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The last decade has witnessed a significant swing towards 
serious infection caused by gram-positive bacteria 
especially those that have developed resistance to a 
variety of antibacterial agents. This change has had 
a profound effect on the treatment options available 
especially for immunocompromised patients. Such 
patients are especially at risk of life-threatening 
bacteraemic episodes caused by staphylococci and 
enterococci in particular. 
Many hospitals are experiencing underlying levels 
of infection with these bacteria approaching 30-3.5%. 
Notably we recognise methicillin-resistant Staphylococcus 
aureus (MRSA) often with additional antibiotic-resist- 
ance determinants (including that to the glycopeptides) 
and vancomycin resistant Enterococcus faecium and E. 
faecalis. Even the once susceptible Streptococcus pneu- 
moniae has now developed resistance to penicillin and 
erythromycin. Increased usage of antibiotics in hospitals 
and elsewhere has exerted selective pressure on Gram- 
positive pathogens especially resulting in an increased 
incidence of multiresistant strains. 
In response there has been renewed interest in anti- 
bacterial agents whose spectrum of activity is focused 
mainly on staphylococci and streptococci. For example, 
good activity has been demonstrated with a strepto- 
gramin complex, an oxazolidinone, a ketolide, a quino- 
lone, and a lipopeptide. It should be noted that each of 
these agents (apart from the ketolide and quinolone) 
are novel compounds with new modes of action and 
therefore less likely to develop resistance mechanisms 
provided they are used conservatively in treatment. 
Nevertheless we are only too aware that resistance will 
develop to these agents; indeed long-term therapy of 
an immunocompromised patient is likely to trigger 
development of such resistance. 
Does the resistance epidemiology demand new 
antibiotics? 
David M. Livermore 
Antibiotic Resistance and Monitoring Reference 
Laboratory, 61 Colindale Avenue, London 
Multiresistance is increasingly prevalent in many 
pathogens, although the extent of the problem varies 
hugely between countries, hospitals, and units within 
hospitals. Resistance rates are notoriously highest in 
many newly prosperous developing countries and in 
those milieux where antibiotic use is of necessity high 
intensive care units. Counterwise, resistance rates are 
generally low in Scandinavia and the Netherlands. 
In the case of gram-positive pathogens, concern about 
resistance centres upon the mounting prevalence 
rates of methicillin-resistant staphylococci (MI&A) 
vancomycin-resistant enterococci (VRE) and penicillin/ 
macrolide-resistant pneumococci. Among gram-negative 
bacteria the greatest concerns are the small but growing 
numbers of P aeruginosa and A. baumannii isolates that 
are now susceptible only to polymyxins. 
MRSA presently account for over 30% of S. aureus 
isolates from bacteremias in the USA, East Asia, much 
of southern Europe, the UK, and Eire. Within these 
countries, most MRSA infection is clonal and reflects 
cross infection rather than new evolution. Thus, for 
example, the explosion in MRSA rates in the UK in the 
mid-1990s was co-incident with the emergence of two 
new “epidemic” strains, EMRSA 1.5 and 16, and these 
now account for over 95% of MRSA bacteraemias in 
the country. MRSA have a variable range of resistances 
to other drugs, dependent on the particular strain; they 
mostly remain susceptible to glycopeptides, although 
resistance is occasionally reported, particularly to 
teicoplanin. VRE have a broader spectrum of resistance 
than MRSA, not least because most of the vancomycin 
resistance is concentrated in E. faecium, a species with 
inherent resistance to all p-lactams, as well as frequent 
acquired resistance to other drug classes. Among E. 
faecium isolates, high vancomycin resistance rates 
(>25%) are seen in the USA, UK and Spain whereas 
rates are low in Scandinavia and, more surprisingly, in 
Southeast Asia. Vancomycin resistance is lo-fold less 
frequent in E. faecalis that E. faecium, but does seem 
to be increasing in the UK and USA, especially among 
isolates from more serious infections. In the case of 
S. pneumoniae, the major problem is the international 
spread of a few lineages, mostly of serotype 6,9,14,15, 
19 and 23, with resistance to penicillin, macrolides and 
tetracyclines. These are highly prevalent in Southeast 
Asia, the USA, and southern Europe but much scarcer 
in northern Europe (except Eire). 
Part of the response to multiresistance must lie in 
the better and lesser use of antibiotics together with- 
especially against MRSA-better infection control 
within hospitals. Experience, however, suggests that any 
decline in resistance achieved by these measures will 
be slow and uncertain. For that reason, continued anti- 
microbial development remains vital and, despite recent 
concerns, is continuing. In particular, new anti-gram- 
positive agents are being developed and launched: 
quinupristin/dalfopristin and linezolid have become 
available during the past two years whilst daptomycin, 
tigecycline and oritavancin are anticipated during the 
next three. Of the two agents recently launched, quinu- 
pristin/dalfopristin is widely active against gram-positive 
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cocci except E. faecalis, although a few strains of 
staphylococci and E. faecium with acquired resistance 
contingent on efflux or acetylation of dalfopristin. 
Linezolid has near-universal activity against gram- 
positive cocci, with MICs narrowly distributed from 0.5 
-4 mg/L. Linezolid-resistance has only been encountered 
in a few mutants of enterococci and one MRSA, 
virtually all of them selected during therapy in under- 
dosed patients or those with indwelling devices or 
difficult-to-reach infections. 
Agents such as linezolid give vital new options 
against gram-positive bacteria. Increasingly, therefore, 
the centre of concern must swing back to gram-negative 
bacteria, where pan-resistance is emerging in a few non- 
fermenters - mostly P aeruginosa from cystic fibrosis in 
the West, but more widely among pseudomonads and 
Acinetobacter spp. in East Asia. Against these organisms 
there is a dearth of advanced antimicrobial develop- 
ments although carbapenemase inhibitors, efflux in- 
hibitors and antimicrobial peptides all provide prospects 
for the more distant future. 
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Infections with a variety of agents cause major prob- 
lems in the immunocompromised host. In addition to 
infection control techniques, a number of strategies 
utilizing antimicrobial agents have been employed: 
therapeutic use for documented infections; preemptive 
use for suspected infections; and prophylactic use 
to prevent infection in high-risk patients. Among 
the major risk factors for bacterial infections in the 
immunocompromised host are neutropenia, breakdown 
in mucosal protective barriers secondary to immuno- 
suppressive agents, and contamination of surgical 
procedures (especially in solid organ transplants) as 
well as the further immunosuppressive effects of 
opportunistic (especially viral) infections. It is the use of 
antimicrobial agents in this setting that is the major 
factor in selecting for resistant bacteria. In some cases, 
the organisms emerge because they are not included 
in the spectrum of activity of the drug being utilized. 
In other cases, antibiotic use results in the selection of 
resistant bacteria originally in the spectrum of the 
agent being utilized. Examples of this are seen in the 
studies in which earlier generation fluoroquinolones 
(which lacked outstanding coverage against Gram- 
positive bacteria) were used for prophylaxis in neutro- 
penic patients; and as a result of this, the patients 
undergoing such prophylaxis showed a marked increase 
in incidence of infections due to viridans streptococci. 
The addition of penicillin to the regimen initially 
suppressed the viridans streptococcal infections, but 
resulted in the emergence of penicillin-resistant viridans 
streptococci. Indeed, it is often possible to predict the 
organisms likely to emerge in the setting of extensive 
antimicrobial use for therapy or prophylaxis. Extensive 
use of expanded-spectrum cephalosporins often results 
in the emergence of Enterobacter cloacae, Entero- 
bacteriaceae with extended-spectrum beta-lactamases, 
vancomycin-resistant enterococci, and nonfermenting 
organisms such as B. cepacia, Acinetobacter species, 
etc. The use of beta-lactam/beta-lactamase inhibitors 
often results in the emergence of MRSA, or Entero- 
bacteriaceae with inhibitor-resistant beta-lactamases. 
Substituting carbapenems also selects for MRSA, 
Stenotrophomonas maltophilia, Serratia marcescens with 
carbapenemases, or vancomycin-resistant Enterococcus 
faecium. As noted before, the earlier generation fluoro- 
quinolones often selected Gram-positive organisms, 
but the newer fluoroquinolones can select for MRSA, 
or fluoroquinolone-resistant Enterobacteriaceae and/or 
Pseudomonas aeruginosa. Extensive use of vancomycin 
or teicoplanin is responsible for the emergence of 
vancomycin-resistant enterococci and strains of S. 
aureus with intermediate resistance to glycopeptides 
(GISA). Many of these organisms are Gram-negative, 
but the Gram-positive bacteria have become a major 
problem in the immunocompromised host in recent 
years. Among the important Gram-positive organisms 
causing problems in this setting are methicillin- and 
fluoroquinolone-resistant S. aureus, methicillin-resistant 
coagulase-negative staphylococci, beta-lactam-resistant 
viridans streptococci, and vancomycin-resistant entero- 
cocci. Interestingly, three of the four of these organisms 
are bacteria that are usually considered to be of relatively 
low virulence and are part of the normal human bacterial 
flora. However, it is the resistance to antimicrobial 
agents in these organisms that makes them dangerous in 
the immunocompromised host. 
The development of resistance to antimicrobial agents 
in bacteria occurs by one of two mechanisms: chromo- 
somal mutation or dissemination of resistance genes 
among microorganisms. These two mechanisms of 
resistance have clinical significance. Emergence caused 
by chromosomal mutation is a rare event and is stable 
when it occurs. It involves a single strain, a single 
resistance gene and is selected for at the site of infection. 
It is selected by a specific antimicrobial given to a specific 
patient and the resistant clones can lead to therapeutic 
failure or disseminate through cross-infection. Antibiotic 
combinations may prevent the selection of resistance 
due to chromosomal mutation. On the other hand, 
resistance related to the dissemination of resistance 
genes among microorganisms (eg, plasmid- or trans- 
poson-mediated resistance) is a relatively frequent event 
and of variable stability. It involves two strains of bacteria 
and often involves multiple resistance determinants. 
Selection is frequently at a site other than that of 
